Differential effects of haloperidol and olanzapine on levels of vascular endothelial growth factor and angiogenesis in rat hippocampus

Schizophrenia Research

Volumn 87, Issue 1-3, 2006, Pages 48-59

  Pillai, Anilkumar ^a   Mahadik, Sahebarao P ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Angiogenesis; Antipsychotics; VEGF

Indexed keywords

DRINKING WATER; HALOPERIDOL; LAMININ; OLANZAPINE; RECA PROTEIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHRONOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MALE; MENTAL DISEASE; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; RAT; WESTERN BLOTTING;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOTTING, WESTERN; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; HALOPERIDOL; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MALE; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 33748886365     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2006.06.017     Document Type: Article

References (69)

1. Abbott N.J. Astrocyte-endothelial interactions and blood-brain barrier permeability. J. Anat. 200 (2002) 629-638
2. Andreasen N.C., O'Leary D.S., Flaum M., Nopoulos P., Watkins G.L., Boles Ponto L.L., and Hichwa R.D. Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naive patients. Lancet 349 (1997) 1730-1734
3. Angelucci F., Aloe L., Gruber S.H., Fiore M., and Mathe A.A. Chronic antipsychotic treatment selectively alters nerve growth factor and neuropeptide Y immunoreactivity and the distribution of choline acetyl transferase in rat brain regions. Int. J. Neuropsychopharmacol. 3 (2000) 13-25
4. Bai O., Chlan-Fourney J., Bowen R., Keegan D., and Li X.M. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J. Neurosci. Res. 71 (2003) 127-131
5. Barch D.M., Carter C.S., Braver T.S., Sabb F.W., MacDonald III A., Noll D.C., and Cohen J.D. Selective deficits in prefrontal cortex function in medication-naive patients with schizophrenia. Arch. Gen. Psychiatry 58 (2001) 280-288
6. Bartlett E.J., Brodie J.D., Simkowitz P., Schlosser R., Dewey S.L., Lindenmayer J.P., Rusinek H., Wolkin A., Cancro R., and Schiffer W. Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients. Am. J. Psychiatry 155 (1998) 337-343
7. Buchsbaum M.S., Potkin S.G., Siegel Jr. B.V., Lohr J., Katz M., Gottschalk L.A., Gulasekaram B., Marshall J.F., Lottenberg S., Teng C.Y., et al. Striatal metabolic rate and clinical response to neuroleptics in schizophrenia. Arch. Gen. Psychiatry 49 (1992) 966-974
8. Buckley P.F. Broad therapeutic uses of atypical antipsychotic medications. Biol. Psychiatry 50 (2001) 912-924
9. Bymaster F.P., Hemrick-Luecke S.K., Perry K.W., and Fuller R.W. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, (1-adrenergic) and muscarinic receptors in vivo in rats. Psychopharmacology (Berlin) 124 (1996) 87-94
10. Casella G.T., Marcillo A., Bunge M.B., and Wood P.M. New vascular tissue rapidly replaces neural parenchyma and vessels destroyed by a contusion injury to the rat spinal cord. Exp. Neurol. 173 (2002) 63-76
11. Casey D.E. Motor and mental aspects of extrapyramidal syndromes. Int. Clin. Psychopharmacol. 10 (1995) 105-114
12. Chakos M.H., Lieberman J.A., Bilder R.M., Borenstein M., Lerner G., Bogerts B., Wu H., Kinon B., and Ashtari M. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am. J. Psychiatry 151 (1994) 1430-1436
13. Chakos M.H., Schobel S.A., Gu H., Gerig G., Bradford D., Charles C., and Lieberman J.A. Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia. Br. J. Psychiatry 186 (2005) 26-31
14. Chiodo L.A., and Bunney B.S. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J. Neurosci. 3 (1983) 1607-1619
15. Dawson N.M., Hamid E.H., Egan M.F., and Meredith G.E. Changes in the pattern of brain-derived neurotrophic factor immunoreactivity in the rat brain after acute and subchronic haloperidol treatment. Synapse 39 (2001) 70-81
16. de Erausquin G.A. Mechanism of molecular action of neuroleptics. Vertex 14 (2003) 36-44
17. Didriksen M. Effects of antipsychotics on cognitive behavior in rats using the delayed non-match to position paradigm. Eur. J. Pharmacol. 28 (1995) 241-250
18. Duijvestijn A.M., van Goor H., Klatter F., Majoor G.D., van Bussel E., and van Breda Vriesman P.J. Antibodies defining rat endothelial cells: RECA-1, a pan-endothelial cell-specific monoclonal antibody. Lab. Invest. 66 (1992) 459-466
19. Dvorak H.F., Brown L.F., Detmar M., and Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146 (1995) 1029-1039
20. Gerber H.P., McMurtrey A., Kowalski J., Yan M., Keyt B.A., Dixit V., and Ferrara N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 273 (1998) 30336-30343
21. Gerber H.P., Malik A.K., Solar G.P., Sherman D., Liang X.H., Meng G., Hong K., Marsters J.C., and Ferrara N. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417 (2002) 954-958
22. Greenberg D.A., and Jin K. From angiogenesis to neuropathology. Nature 438 (2005) 954-959
23. Harrison R.V., Harel N., Panesar J., and Mount R.J. Blood capillary distribution correlates with hemodynamic-based functional imaging in cerebral cortex. Cereb. Cortex 12 (2002) 225-233
24. Jibson M.D., and Tandon R. New atypical antipsychotic medications. J. Psychiatr. Res. 32 (1998) 215-228
25. Jin K., Zhu Y., Sun Y., Mao X.O., Xie L., and Greenberg D.A. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 11946-11950
26. Kapur S., Arenovich T., Agid O., Zipursky R., Lindborg S., and Jones B. Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am. J. Psychiatry 162 (2005) 939-946
27. Keshavan M.S., Rosenberg D., Sweeney J.A., and Pettegrew J.W. Decreased caudate volume in neuroleptic-naive psychotic patients. Am. J. Psychiatry 155 (1998) 774-778
28. Kim J.J., Mohamed S., Andreasen N.C., O'Leary D.S., Watkins G.L., Boles Ponto L.L., and Hichwa R.D. Regional neural dysfunctions in chronic schizophrenia studied with positron emission tomography. Am. J. Psychiatry 157 (2000) 542-548
29. Kinon B.J., and Lieberman J.A. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology (Berlin) 124 (1996) 2-34
30. Kremer C., Breier G., Risau W., and Plate K.H. Up-regulation of flk-1/vascular endothelial growth factor receptor 2 by its ligand in a cerebral slice culture system. Cancer Res. 57 (1997) 3852-3859
31. Kuo N.T., Benhayon D., Przybylski R.J., Martin R.J., and LaManna J.C. Prolonged hypoxia increases vascular endothelial growth factor mRNA and protein in adult mouse brain. J. Appl. Physiol. 86 (1999) 260-264
32. Lahti A.C., Holcomb H.H., Medoff D.R., Weiler M.A., Tamminga C.A., and Carpenter Jr. W.T. Abnormal patterns of regional cerebral blood flow in schizophrenia with primary negative symptoms during an effortful auditory recognition task. Am. J. Psychiatry 158 (2001) 1797-1808
33. Lahti A.C., Holcomb H.H., Weiler M.A., Medoff D.R., and Tamminga C.A. Functional effects of antipsychotic drugs: comparing clozapine with haloperidol. Biol. Psychiatry 53 (2003) 601-608
34. Lahti A.C., Weiler M.A., Medoff D.R., Tamminga C.A., and Holcomb H.H. Functional effects of single dose first- and second-generation antipsychotic administration in subjects with schizophrenia. Psychiatry Res. 139 (2005) 19-30
35. Larrivee B., and Karsan A. Signaling pathways induced by vascular endothelial growth factor (review). Int. J. Mol. Med. 5 (2000) 447-456
36. Leucht S., Busch R., Hamann J., Kissling W., and Kane J.M. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol. Psychiatry 57 (2005) 1543-1549
37. Lieberman J.A., Tollefson G., Tohen M., Green A.I., Gur R.E., Kahn R., McEvoy J., Perkins D., Sharma T., Zipursky R., Wei H., Hamer R.M., and HGDH Study Group. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am. J. Psychiatry 160 (2003) 1396-1404
38. Mahadik S.P., Laev H., Korenovsky A., and Karpiak S.E. Haloperidol alters rat CNS cholinergic system: enzymatic and morphological analyses. Biol. Psychiatry 24 (1988) 199-217
39. Maragnoli M.E., Fumagalli F., Gennarelli M., Racagni G., and Riva M.A. Fluoxetine and olanzapine have synergistic effects in the modulation of fibroblast growth factor 2 expression within the rat brain. Biol. Psychiatry 55 (2004) 1095-1102
40. McClure R.J., Keshavan M.S., and Pettegrew J.W. Chemical and physiologic brain imaging in schizophrenia. Psychiatry Clin. North Am. 21 (1998) 93-122
41. Medoff D.R., Holcomb H.H., Lahti A.C., and Tamminga C.A. Probing the human hippocampus using rCBF: contrasts in schizophrenia. Hippocampus 11 (2001) 543-550
42. Meyer-Lindenberg A.S., Olsen R.K., Kohn P.D., Brown T., Egan M.F., Weinberger D.R., and Berman K.F. Regionally specific disturbance of dorsolateral prefrontal-hippocampal functional connectivity in schizophrenia. Arch. Gen. Psychiatry 62 (2005) 379-386
43. Miller D.D., Andreasen N.C., O'Leary D.S., Rezai K., Watkins G.L., Ponto L.L., and Hichwa R.D. Effect of antipsychotics on regional cerebral blood flow measured with positron emission tomography. Neuropsychopharmacology 17 (1997) 230-240
44. Miller D.D., Andreasen N.C., O'Leary D.S., Watkins G.L., Boles Ponto L.L., and Hichwa R.D. Comparison of the effects of risperidone and haloperidol on regional cerebral blood flow in schizophrenia. Biol. Psychiatry 49 (2001) 704-715
45. Mortimer A.M. Novel antipsychotics in schizophrenia. Expert Opin. Investig. Drugs 13 (2004) 315-329
46. Palmer T.D., Willhoite A.R., and Gage F.H. Vascular niche for adult hippocampal neurogenesis. J. Comp. Neurol. 425 (2000) 479-494
47. Parikh V., Khan M.M., and Mahadik S.P. Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J. Psychiatr. Res. 37 (2003) 43-51
48. Parikh V., Khan M.M., and Mahadik S.P. Olanzapine counteracts reduction of brain-derived neurotrophic factor and TrkB receptors in rat hippocampus produced by haloperidol. Neurosci. Lett. 356 (2004) 135-139
49. Parikh V., Terry A.V., Khan M.M., and Mahadik S.P. Modulation of nerve growth factor and choline acetyltransferase expression in rat hippocampus after chronic exposure to haloperidol, risperidone, and olanzapine. Psychopharmacology (Berlin) 172 (2004) 365-374
50. Parikh V., Khan M.M., Terry A., and Mahadik S.P. Differential effects of typical and atypical antipsychotics on nerve growth factor and choline acetyltransferase expression in the cortex and nucleus basalis of rats. J. Psychiatr. Res. 38 (2004) 521-529
51. Pillai A., Sharma S., and Mahadik S.P. Modulation of BDNF levels by antipsychotics regulates their temporal effects on neurogenesis in hippocampus. Biol. Psychiatry 57 (2005) 201S
52. Pillai A., Terry Jr. A.V., and Mahadik S.P. Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. Schizophr. Res. 82 (2006) 95-106
53. Richelson E. Preclinical pharmacology of neuroleptics: focus on new generation compounds. J. Clin. Psychiatry 57 Suppl. 11 (1996) 4-11
54. Riva M.A., Molteni R., Tascedda F., Massironi A., and Racagni G. Selective modulation of fibroblast growth factor-2 expression in the rat brain by the atypical antipsychotic clozapine. Neuropharmacology 38 (1999) 1075-1082
55. Sharma T., and Mockler D. The cognitive efficacy of atypical antipsychotics in schizophrenia. J. Clin. Psychopharmacol. 18 (1998) 12S-19S
56. Skarsfeldt T. Differential effect of antipsychotics on place navigation of rats in Morris water maze. A comparative study between novel and reference antipsychotics. Psychopharmacology (Berlin) 124 (1996) 126-133
57. Terry Jr. A.V., Hill W.D., Parikh V., Evans D.R., Waller J.L., and Mahadik S.P. Differential effects of chronic haloperidol and olanzapine exposure on brain cholinergic markers and spatial learning in rats. Psychopharmacology (Berlin) 164 (2002) 360-368
58. Terry Jr. A.V., Hill W.D., Parikh V., Waller J.L., Evans D.R., and Mahadik S.P. Differential effects of haloperidol, risperidone, and clozapine exposure on cholinergic markers and spatial learning performance in rats. Neuropsychopharmacology 28 (2003) 300-309
59. Terry Jr. A.V., Parikh V., Gearhart D.A., Pillai A., Hohanadel E., Warner S., Nasrallah H.A., and Mahadik S.P. Time Dependent Effects of Haloperidol and Ziprasidone on Nerve Growth Factor, Cholinergic Neurons, and Spatial Learning in Rats. J. Pharmacol. Exp. Ther. 318 (2006) (in press)
60. Thomas K.A. Vascular endothelial growth factor, a potent and selective angiogenic agent. J. Biol. Chem. 271 (1996) 603-606
61. Thompson J.K., Peterson M.R., and Freeman R.D. Single-neuron activity and tissue oxygenation in the cerebral cortex. Science 299 (2003) 1070-1072
62. Tollefson G.D. Cognitive function in schizophrenic patients. J. Clin. Psychiatry 57 (1996) 31-39
63. Vaiva G., Thomas P., Llorca P.M., Dupont S., Cottencin O., Devos P., Mazas O., Rascle C., Steinling M., and Goudemand M. SPECT imaging, clinical features, and cognition before and after low doses of amisulpride in schizophrenic patients with the deficit syndrome. Psychiatry Res. 115 (2002) 37-48
64. Weinberger D.R., Berman K.F., and Illowsky B.P. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism. Arch. Gen. Psychiatry 45 (1988) 609-615
65. Wirtshafter D., and Asin K.E. Effects of haloperidol and clozapine on Fos expression in the primate striatum. NeuroReport 14 (2003) 2429-2432
66. Wiser A.K., Andreasen N.C., O'Leary D.S., Watkins G.L., Boles Ponto L.L., and Hichwa R.D. Dysfunctional cortico-cerebellar circuits cause 'cognitive dysmetria' in schizophrenia. NeuroReport 9 (1998) 1895-1899
67. Wright I.C., Rabe-Hesketh S., Woodruff P.W., David A.S., Murray R.M., and Bullmore E.T. Meta-analysis of regional brain volumes in schizophrenia. Am. J. Psychiatry 157 (2000) 16-25
68. Zand L., Ryu J.K., and McLarnon J.G. Induction of angiogenesis in the beta-amyloid peptide-injected rat hippocampus. NeuroReport 16 (2005) 129-132
69. Zonta M., Angulo M.C., Gobbo S., Rosengarten B., Hossmann K.A., Pozzan T., and Carmignoto G. Neuron-to-astrocyte signaling is central to the dynamic control of brain microcirculation. Nat. Neurosci. 6 (2003) 43-50